Use of Titration as a Therapeutic Individualization Strategy: An Analysis of Food and Drug Administration–Approved Drugs
Selecting a dose regimen that is both safe and effective for patients is one of the most critical elements of a successful drug development program. Titrating the dose regimen of a drug based on patient response may help to identify safe and effective dosages at the individual patient level. Therefo...
Main Authors: | Robert N. Schuck, Michael Pacanowski, Sarah Kim, Rajanikanth Madabushi, Issam Zineh |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-05-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.12626 |
Similar Items
-
The clinical pharmacogeneticist: An emerging regulatory scientist at the US Food and Drug Administration
by: Zineh Issam, et al.
Published: (2010-04-01) -
Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations
by: Di Maria Jiang, et al.
Published: (2019-04-01) -
The art and science of drug titration
by: Aisling R. Caffrey, et al.
Published: (2020-09-01) -
Defibrotide (Defitelio): A New Addition to the Stockpile of Food and Drug Administration-approved Oligonucleotide Drugs
by: Cy Stein, et al.
Published: (2016-01-01) -
Food and Drug Administration approvals in phase 3 Cancer clinical trials
by: Joseph Abi Jaoude, et al.
Published: (2021-06-01)